Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
Símbolo de cotizaciónAVR
Nombre de la empresaAnteris Technologies Global Corp
Fecha de salida a bolsaDec 13, 2024
Director ejecutivoMr. Wayne G. Paterson
Número de empleados136
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 13
Dirección860 Blue Gentian Road
CiudadEAGAN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal55121
Teléfono16514930606
Sitio Webhttps://anteristech.com/
Símbolo de cotizaciónAVR
Fecha de salida a bolsaDec 13, 2024
Director ejecutivoMr. Wayne G. Paterson
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos